Vaccines

July 12, 2024

Wesley Self named to leadership role in global clinical trials network

The Strategies and Treatments for Respiratory Infections and Viral Emergencies network includes more than 300 sites around the world and international experts in clinical trials, infectious diseases, critical care and pandemic preparedness.

By Bill Snyder
June 28, 2024

Antibody trial launched to address enterovirus threat

Enterovirus D68 has caused an increasing number of infections during the past decade and is associated with acute flaccid myelitis, a polio-like condition that mostly affects children and causes sudden weakness and paralysis.

By Bill Snyder
June 12, 2024

Scientists find antibodies that block parainfluenza virus infection

The antibodies may have clinical benefit as antiviral drugs to treat potentially life-threatening infections in elderly and immunosuppressed patients.

By Bill Snyder
May 31, 2024

Antibodies may aid effort to fight influenza B: study

The findings reported in the journal Immunity support the development of a monoclonal antibody for prevention and treatment of influenza B — and will help guide efforts to develop a universal influenza vaccine.

By Bill Snyder
(iStock image)
April 3, 2024

Talbot leads US immunization committee

Infectious diseases researcher H. Keipp Talbot, MD, MPH, has been appointed chair of the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention.

By Paul Govern
3d rendering white blood cells with red blood cells
March 14, 2024

Immune cell profiles may guide flu vaccine timing in pediatric stem cell transplant patients

A new study led by Vanderbilt University Medical Center researchers has identified key immune cell populations that predict how well pediatric hematopoietic stem cell transplant (HCT) recipients will respond to the influenza vaccine.

By Paul Govern
January 17, 2024

Bird flu vaccine more effective with potent adjuvant

The avian (bird) influenza vaccine creates a more robust immune response when paired with a potent ingredient known as an adjuvant, according to Vanderbilt research published in The Journal of Infectious Diseases.
By Craig Boerner
November 6, 2023

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.
By Bill Snyder
September 13, 2023

James Crowe’s antibody research lands American Society for Microbiology Award

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.
By Bill Snyder
July 13, 2023

VIGH, partners get training grant to create vaccine-related research in Peru

In partnership with the Universidad Peruana Cayetano Heredia (UPCH) and the Instituto de Investigacion Nutricional (IIN), the Vanderbilt Institute for Global Health (VIGH) has received $1.2 million for a five-year training grant funded by the Fogarty International Center to establish the Peru-Vanderbilt Prevention through Vaccination Training program.
By Kristin Centers
June 22, 2023

VUMC, Oxford team develops ‘blueprint’ to block lethal virus

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.
By Bill Snyder
April 24, 2023

Study finds early RSV infection linked to significantly increased risk of asthma in children

A Vanderbilt study has found that RSV infection in the first year of life is associated with a significantly increased risk of asthma in children.
By Nancy Humphrey
March 30, 2023

NIH grant launches C. diff vaccine research initiative

Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.
By Anthony Czelusniak